

EW

ARNOLD & PORTER LLP

202.942.5000
202.942.5999 Fax
555 Twelfth Street, NW
Washington, DC 20004-1206

April 11, 2005



Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Application No. 09/719,410
Filed: December 12, 2000
Title: **Glucagon-Like Peptide-1 Improves β -Cell
Response to Glucose in Subjects with Impaired
Glucose Tolerance**
Applicants: Burkhard GÖKE *et al.*
Atty. Docket: 18528.543

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office (PTO):

1. a Supplemental Information Disclosure Statement;
2. a PTO-1449 form (1 page) with four accompanying references; and
3. a return postcard.

Please stamp the attached postcard with the filing date of these documents and return it to our courier.


In the event that extensions of time beyond are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned. Applicants do not believe any additional fees are due in conjunction with this filing. However, if any additional fees are required in the present application, including any fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387, referencing matter number 18528.543. A duplicate copy of this letter is enclosed.

Respectfully submitted,

Rachel L. Adams

David R. Marsh (Reg. No. 41,408)
Rachel L. Adams (Reg. No. 54,660)
Thomas E. Holsten (Reg. No. 46,098)

Attachments



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Burkhard GÖKE *et al.*

Appln. No.: 09/719,410

Filed: December 12, 2000

For: **Glucagon-Like Peptide-1 Improves β -
Cell Response to Glucose in Subjects
with Impaired Glucose Tolerance**

Art Unit: 1653

Examiner: A. Mohamed

Confirmation No.: 8826

Atty. Docket: 18528.543

Supplemental Information Disclosure Statement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The attention of the Examiner is invited to the documents listed on the attached Form PTO-1449. Copies of the listed documents are submitted herewith.


It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

CERTIFICATION AND/OR FEE

Applicants certify that each of the documents listed on the attached Form PTO-1449 was first cited in a communication from a foreign patent office in a counterpart foreign application

not more than three months prior to the filing of this Supplemental Information Disclosure Statement and, therefore, no fee is required.


Respectfully submitted,

A handwritten signature in cursive script that reads "Rachel L. Adams". The signature is written in black ink and is positioned above the printed names of the signatories.

David R. Marsh (Reg. No. 41,408)
Rachel L. Adams (Reg. No. 54,660)
Thomas E. Holsten (Reg. No. 46,098)

Date: April 11, 2005

ARNOLD & PORTER LLP
555 Twelfth Street, N.W.
Washington, D.C. 20004-1206
(202) 942-5000 telephone
(202) 942-5999 facsimile



FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

18528.543 / 0206-UTL-9

APPLICATION NO.

09/719,410

APPLICANTS

Burkhard GÖKE *et al.*

FILING DATE

December 12, 2000

GROUP

1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AF1						Yes No
	AG1						Yes No
	AH1						Yes No
	AI1						Yes No
	AJ1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AK1	D'ALESSIO <i>et al.</i> , "Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons", <u>The Journal of Clinical Investigation</u> , Vol. 97, No. 1, pp. 133-138 (1996)
	AL1	European Search Report published January 12, 2005 in European Patent Application No. 04075402.0
	AM1	RITZEL <i>et al.</i> , "A synthetic glucagon-like peptide-1 analog with improved plasma stability", <u>Journal of Endocrinology</u> , Vol. 159, pp. 93-102 (1998)
	AN1	SCHIRRA <i>et al.</i> , "Exendin(9-39)amide is an Antagonist of Glucagon-like Peptide-1(7-36)amide in Humans", <u>J. Clin. Invest.</u> , Vol. 101, No. 7, pp. 1421-1430 (1998)
	AO1	
	AP1	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.